Lenalidomide, an orally administered immune-modulating drug, has several mechanisms of action against multiple myeloma (MM). However, the mechanisms of action of immune-modulating drugs are not understood completely. Lenalidomide maintenance therapy prolongs the time to progression and increases the overall survival in patients with MM. However, secondary primary malignancy (SPM) has been noted as a serious adverse event in patients with MM treated with lenalidomide. Lenalidomide treatment is not covered by insurance. Consequently, physicians have little experience with the adverse events of lenalidomide treatment in patients with MM. Here, we describe a case of breast cancer after lenalidomide treatment for MM. To our knowledge, this is the first report of a lenalidomide-associated SPM in Korea. The risk factors associated with lenalidomide-associated SPM should be considered carefully when implementing chemotherapy regimens in patients with MM. ( Korean J Med 2014;86:353-356) Keywords: Multiple myeloma; Lenalidomide; Breast cancer; Secondary primary malignancy 서 론 다발골수종은 골수 내의 형질세포의 단클론성 확장으로 인하여 단클론성 면역글로불린이 생산되는 것으로 범혈구감 소증, 면역저하, 골용해성 병변, 고칼슘혈증, 신부전을 특징 으로 한다[1]. 여러 연구에서 재발 및 불응성의 다발골수종 환자에서 lenalidomide와 dexamethasone의 병합요법을 시행하였을 때 반응률이 높아지고 질병의 진행을 늦추며 생존율을 향상시 키는 데 도움이 된다고 알려져 있다. 또한 자가조혈모세포이 식 이후에도 lenalidomide 유지요법은 질병의 진행을 늦추고 생존율을 향상시킨다[2-4]. 이러한 lenalidomide의 치료에서 주요한 부작용으로는 백혈구감소증과 정맥혈전증, 이차성 원발 종양의 발생빈도도 높게 나타난다[5-7].
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